Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 385; no. 24; pp. 2252 - 2263
• Main Authors: Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 09.12.2021
• Subjects: Adverse events; Aged; Albumin; Albuminuria - etiology; Angiotensin; Cardiology; Cardiology General; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cerebral infarction; Chronic Kidney Disease; Clinical medicine; Congestive heart failure; Creatinine; Design; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Double-Blind Method; Endocrinology; Epidermal growth factor receptors; Female; Glomerular filtration rate; Heart failure; Hospitalization; Humans; Hyperkalemia; Kidney diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - adverse effects; Mineralocorticoid Receptor Antagonists - therapeutic use; Myocardial infarction; Naphthyridines - adverse effects; Naphthyridines - therapeutic use; Nephrology; Patient safety; Placebos; Potassium; Proportional Hazards Models; Renal failure; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; Renin
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2110956

In this double-blind trial, patients with stage 1 to 4 chronic kidney disease and type 2 diabetes were randomly assigned to receive finerenone or placebo. Finerenone treatment was superior with regard to the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.